Rocket Doctor AI

Rocket Doctor AI AAQS

Delisted

The The AAQS of Rocket Doctor AI (TRUE.CN) as of Nov 16, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Rocket Doctor AI has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Rocket Doctor AI in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Rocket Doctor AI AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
1.00 CAD
Jan 1, 2018
1.00 CAD
Jan 1, 2019
1.00 CAD
Jan 1, 2020
1.00 CAD
Jan 1, 2021
1.00 CAD
Jan 1, 2022
1.00 CAD
Jan 1, 2023
1.00 CAD
Jan 1, 2024
1.00 CAD
The Rocket Doctor AI AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rocket Doctor AI Stock analysis

What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs. The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy. Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rocket Doctor AI stock

The AAQS of Rocket Doctor AI is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Rocket Doctor AI

All Key Metrics — Rocket Doctor AI